Accordingly, a recent study implied that p62/SQSTM1 is highly phosphorylated at serine 349 in the tumor tissues of HCV-positive HCC patients and that phosphorylated p62/SQSTM1 drives the glucoronate and glutathione synthesis pathways to enhance drug resistance and malignancy of liver cancer [453]. This evidence concerns the gene SQSTM1 and neoplasm.